Business Context and Reporting Period
KALA BIO, Inc. (KALA) filed a Form 8-K on January 20, 2026, reporting a regulatory event concerning its listing status on The Nasdaq Capital Market. The company is incorporated in Delaware and headquartered in Arlington, MA.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial metric disclosed is the stock price performance triggering the listing deficiency.
Material Changes
The material change reported is the failure to meet Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement. Specifically:
- The closing bid price of the Company's common stock was below $1.00 per share for 30 consecutive business days between December 3, 2025, and January 16, 2026.
- The Company received a formal notice of delisting from the Nasdaq Listing Qualifications Department.
Outlook, Risks, and Contingencies
Compliance Period: The Company has been granted an initial 180-calendar-day compliance period ending July 20, 2026, to regain compliance.
Remediation Requirements: To cure the deficiency, the stock must maintain a minimum closing bid price of $1.00 for at least ten consecutive business days during the compliance period.
Secondary Compliance Option: If the initial period is unsuccessful, the Company may be eligible for an additional 180-day period if it meets all other initial listing standards (excluding bid price) and provides written notice of intent to cure, potentially via a reverse stock split.
Risks: There is no assurance the Company will qualify for the additional cure period or that Nasdaq will grant continued listing if the deficiency is not cured. Failure to comply could result in delisting. The Company retains the right to appeal a delisting determination.
Immediate Impact: The stock will continue to be listed and traded on Nasdaq pending the outcome of the compliance period.
Investor Verification Checklist
- Verify the current trading price of KALA stock relative to the $1.00 threshold.
- Monitor the Company's announcements regarding the potential execution of a reverse stock split.
- Review the Company's cash position and burn rate in recent 10-Q or 10-K filings to assess the ability to fund operations if delisting occurs.
- Check for any subsequent 8-K filings regarding the Company's appeal or status updates before the July 20, 2026 deadline.